Yasuaki Sagara, Chief of Breast Oncology at Sagara Hospital, Social Medical Cooperation, shared a post on X:
“VERITAC-2
NEJM 2025: In ESR1 mutation-positive ER+/ HER2- advanced breast cancer, PROTAC-type ER degrader vepdegestrant showed superior PFS improvement over fulvestrant.
Subjects:
- Previously treated ER+/HER2- advanced/ metastatic breast cancer n=624 (ESR1 mutation-positive n=270)
- Progression after 1 or more lines of endocrine therapy
Key Results:
(ESR1 mutation-positive subgroup):
- Median PFS 5.0 vs 2.1 months (HR 0.57, 95%CI 0.42-0.77, p=0.0001)
- ORR 19% vs 4% • No PFS improvement in overall population (ITT)
FDA approval on May 1, 2026, the world’s first approved PROTAC drug. A new option for personalized treatment based on ESR1 mutation detection (liquid biopsy). Clarifying positioning relative to SERENA-6 (camizestrant) will be a key discussion point going forward.”
Title: Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Authors: Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timucin Cil, Katarzyna J. Jerzak, Christian Fuentes, Tetsuhiro Yoshinami, Alvaro Rodriguez-Lescure, Ahmet Sezer, Andrea Fontana, Valentina Guarneri, Andrea Molckovsky, Marie-Ange Mouret-Reynier, Umut Demirci, Yongqiang Zhang, Olga Valota, Dongrui R. Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, Erika P. Hamilton
